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Abstract
Background: This study was conducted to determine whether patients with Gaucher disease had
significant dental pathology because of abnormal bone structure, pancytopenia, and coagulation
abnormalities.
Methods: Each patient received a complete oral and periodontal examination in addition to a
routine hematological evaluation.
Results: Gaucher patients had significantly fewer carious lesions than otherwise healthy carriers.
Despite prevalence of anemia, there was no increase in gingival disease; despite the high incidence
of thrombocytopenia, gingival bleeding was not noted; and despite radiological evidence of bone
involvement, there was no greater incidence loss of teeth or clinical tooth mobility.
Conclusions: These data represent the first survey of the oral health of a large cohort of patients
with Gaucher disease. It is a pilot study of a unique population and the results of the investigation
are indications for further research. Based on our findings, we recommend regular oral
examinations with appropriate dental treatment for patients with Gaucher disease as for other
individuals. Consultation between the dentist and physician, preferably one with experience with
Gaucher disease, should be considered when surgical procedures are planned.
Background
Gaucher disease, the most prevalent lysosomal storage
disorder, is a result of the genetic defect in production of
the enzyme β-glucocerebrosidase, and the consequent
accumulation of the glycolipid, glucocerebroside, in the
cells of the monocyte-macrophage system [1]. The clinical
heterogeneity, which marks all forms of Gaucher disease,
is attributable, to a large extent, to the more than 200
mutations, including point mutations, insertions, dele-
tions, and cross-overs, within the glucocerebrosidase gene
[2]. Classically, three clinical forms have been delineated,
based on the absence (type I) or presence (types II and III)
of neurological signs.
Type I, the non-neuronopathic form, is the most com-
mon, with an ethnic predilection for Ashkenazi Jews.
Onset of symptoms is noted in all ages; neonates as well
as in the elderly. Clinical heterogeneity is characteristic of
type I and the course of the disease is variable. Many
patients with this type are virtually asymptomatic all of
their lives and are diagnosed because of evaluation for an
unrelated medical problem or because of a family
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screening of a symptomatic relative [3]. The presence of
the single most common mutation, N370S (1226G) on
one allele appears to be protective of development of a
neuronopathic form, and the genotype N370S/N370S is
the most common among type I patients [2]. Most other
Ashkenazi Jewish patients are compound heterozygotes
for the N370S (1226G) mutation.
Type II presentation is more acute and typically more uni-
form, with onset of both visceral signs and neurological
involvement during the first six months of life. This
includes hypertonic posturing, strabismus, trismus, and
retroflexion of the head[4]. Aspiration pneumonia and
laryngospasm are often the cause of death, which gener-
ally occurs by two years of age.
Type III may be considered a heterogeneous conglomerate
of patients who present some features in childhood and
who demonstrate at least one neurological sign. Early
cases of this "sub-acute" form of Gaucher disease were rec-
ognized in the Norbottnian-Vesterbottnian territories in
northern Sweden. Symptoms were of mild to moderate
severity and included bone involvement and visceral
enlargement as well as central nervous system findings of
spasticity, seizures, and oculomotor apraxia. A new vari-
ant, called type IIIc, has been described in a few families
from Japan, Israel, and Spain. These patients present with
none of the above common visceral signs, but only with
oculomotor apraxia and a progressive calcification of the
aortic and/or mitral heart valves which has proven to be
fatal in all of the non-Israeli cases [5].
The earliest sign of Gaucher disease is splenomegaly. In
cases where the spleen may not be palpable, this will be
demonstrable on ultrasound examination [6]. Untreated,
there may be progressive organ enlargement, leading to
hypersplenism. In children, growth retardation may be
seen [7]. Anemia and thrombocytopenia, causing easy fat-
igability and a tendency towards bleeding, are among the
earliest presenting signs and most prominent features of
Gaucher disease [1]. Most symptomatic patients have
some degree of liver involvement, usually presenting as
hepatomegaly with or without abnormal liver function
tests. The severity of liver involvement appears to be cor-
related with severe manifestations in other organs [8].
Bone involvement is among the more variable of the
symptoms attributed to Gaucher disease. It is probably
the most debilitating, particularly the recurrent and sud-
den onset of painful "bone crises" that may require nar-
cotic medication for relief. The occurrence of pathological
fractures or fractures following slight trauma (e.g., broken
ribs after an embrace), avascular necrosis of the heads of
femur and humerus, and compression fractures of the
spine are well-documented complications of Gaucher dis-
ease [9].
There are no markers that accurately predict which symp-
toms will occur in any particular patient. The degree of
bone involvement may not be correlated with the severity
of organomegaly or any of the hematological parameters
of Gaucher disease [10,11]. Conversely, asymptomatic
bone disease, such as the Erlenmeyer flask deformity of
the distal femur, medullary infarcts, and osteopenia, are
often only secondary findings in cases of massive visceral
involvement. Thus, bone involvement may or may not be
a presenting feature of Gaucher disease.
The mandible, a long bone, has been noted in anecdotal
case reports as a nidus of Gaucher cell infiltration and/or
bone crisis [12–17]. In our study of a subset of 28 patients
with Gaucher disease (of an initial cohort of 87 patients),
25 patients displayed radiologic evidence of bone involve-
ment in the jaw, including widening of the marrow
spaces, endosteal scalloping, and cortical thinning [18]. A
tendency to bleeding is one of the more common present-
ing signs; hence, prolonged or excessive bleeding after
tooth extraction or other similar invasive dental proce-
dures may induce a patient to seek medical attention.
Therefore, we initiated this study to ascertain whether
patients with Gaucher disease demonstrate greater dental
pathology because of poor underlying bone structure,
whether pancytopenia affects gingival health, and
whether these features of symptomatic Gaucher disease
affect oral health.
Methods
The Shaare Zedek Medical Center referral clinic includes
more than 350 patients with Gaucher disease All
Ashkenazi Jewish patients who appeared for routine med-
ical follow-up examination between March and June of
1996 were invited to participate in the study. Of these 146
patients, 87 consented to have an oral examination. This
study received approval of the Helsinki Committee (Insti-
tutional Review Board). Patients were also asked to sign
an informed consent form.
The diagnosis of Gaucher disease was based on bone mar-
row aspirate and/or enzyme assay, and confirmed by
molecular analysis. The severity of the disease was
assessed by the use of a severity score index (SSI) ranging
from 0–30; indicative of asymptomatic to very severe
involvement [19].
Carriers of Gaucher disease were also enrolled in the
study. Patients were accompanied by first degree relatives
who had previously been diagnosed as carriers of Gaucher
disease both by enzyme analysis and molecular analysis.BMC Oral Health 2003, 3 http://www.biomedcentral.com/1472-6831/3/4
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Each patient received a complete oral examination by an
oral pathologist, using a portable dental chair, with a den-
tal examining light. The oral examination procedure con-
sisted of a complete soft tissue examination and a clinical
examination for decayed, missing and filled surfaces of
teeth (DMFS). As recommended by the World Health
Organization, the DMFS index did not include radio-
graphs [20]. Patients were encouraged to present for pan-
oramic radiographic examination. Twenty eight of the 87
patients agreed. A periodontal examination (GI) was per-
formed, using a modification of the Löe and Sillness Index
[21]. Gingival probing was not done. Hematological tests
were conducted as part of the routine Gaucher-related fol-
low-up, including complete blood count and coagulation
tests, prothrombin time (PT) and partial thromboplastin
time (PTT). No additional hematologic tests were ordered
other than those customarily required for the routine
medical evaluation.
Results
The population studied consisted of 87 patients with Gau-
cher disease (37 males and 50 females). The mean age was
30.7 (range: 4–68) years. Twenty-eight patients (32%)
had been splenectomized prior to the time of the oral
examination. Fifty-three (61%) of these patients were
receiving enzyme replacement therapy with Cerezyme®
(Genzyme Therapeutics Inc., Cambridge MA), the recom-
binant form. [22]. Thirty-one carriers (14 males and 17
females) were examined. Their mean age was 43.7 (range
26–68) years.
The hematological parameters of the patients are pre-
sented in Table 1. Some patients presented with an abnor-
mally prolonged PTT (65%), thrombocytopenia (42%)
and anemia (38%). Although a few patients reported a
history of oral bleeding associated with dental extractions
and/or shedding of deciduous teeth, spontaneous oral
bleeding was not reported.
The oral health status of the patients with Gaucher dis-
ease, as compared to the carriers, is presented in Table 2.
For most dental parameters measured, the findings in the
patients were better than those of the carriers. Patients had
lower levels of caries experience (DMFS) than carriers
(36.8 as compared to 49.4). This difference was statisti-
cally significant at a level of p = 0.048. The largest differ-
ence was for the MS component (missing surfaces).
Among patients, this was 9.5, half the level found among
carriers (18.9). This difference reached high statistical sig-
nificance (p = 0.008). The differences for the filled and
decayed surface components of the DMFS index did not
reach statistical significance. There was no difference in
gingival disease between the patients and the carriers.
Table 1: Hematological parameters of patients with Gaucher disease
Parameter (units) Number of patients* Mean (+/- SD) Normal range Number patients
< normal (%)
Number patients
> normal (%)
PT (%) 82 78.1 (+/-19.2) 66 – 100 18 (22%) 13 (16%)
PTT (seconds) 79 39.8 (+/-11.8) 20 – 32 0 51 (65%)
Platelet count (103/µl) 86 169,500 (+/-113,700) 120,000 – 350,000 36 (42%) 4 (5%)
Hemoglobin (g/dl) 86 12.3 (+/-1.6) 12 – 16 33 (38%) 0
WBC (103/µl) 86 7.7 (+/-3.8) 3.9 – 9.6 8 (9%) 21 (24%)
SD = standard deviation; PT = prothrombin time; PTT = partial thromboplastin time; WBC = white blood cell count. *data not available for all 
patients
Table 2: Age adjusted mean oral health indices (+/- SD) for patients and carriers of Gaucher disease.
Patients n = 87 Carriers n = 31 p value
DMFS* 36.8 (+/- 31.3) 49.4(+/- 35.5) .048
DS* 0.8 (+/- 2.3) 1.5(+/- 4.2) .026
MS* 9.5 (+/- 20.3) 18.9(+/- 32.7) .008
FS* 21.5(+/- 21.8) 28.9(+/- 19.6) NS
GI** 0.7 (+/- 0.48) 0.8 (+/- 0.45) NS
SD = standard deviation; DMFS = decayed, missing and filled surfaces of permanent and deciduous teeth; DS = decayed surfaces; MS = missing sur-
faces; FS = filled surfaces; GI = gingival index. *DMFS, DS, MS, FS, parametric variables were analyzed employing ANOVA. Mean levels were 
adjusted for age. **GI, a non-parametric variable, was analyzed employing the Mann-Whitney test. Due to differences in age distribution, the test 
was applied separately for three age groups (<18, 19–40, and >41 years).BMC Oral Health 2003, 3 http://www.biomedcentral.com/1472-6831/3/4
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No correlation was detected between the DMFS and GI
indices and the clinical signs of Gaucher disease, includ-
ing anemia, thrombocytopenia, status post-splenectomy,
and decreased coagulation times; nor with the SSI.
Discussion
The dental health of the patients, as measured by the
DMFS index, was better than that of the carriers. The
patients had approximately half the number of carious
surfaces and half the number of missing surfaces com-
pared to the carrier cohort. Since the carriers and the
patients are members of the same families, one might
assume a similar socio-economic environment and access
to oral health care. The insignificant difference in filled
surfaces, a measure of dental treatment, supports this
hypothesis. The patients, however, were aware of their
Gaucher disease status and may have had a higher health
awareness, including a greater concern for their oral
health. A healthier diet and better personal oral hygiene
might explain the observed differences in DS and MS
scores.
As Gaucher disease results in anemia, tendency to bleed-
ing, and poor healing, a correlation between Gaucher dis-
ease and gingival disease was anticipated, but no such
association was found. As suggested above, the reason for
this could be that the patients were aware of their "at risk"
status and may have practiced better oral hygiene.
A certain selection bias is recognized in this study. The
patients were told that an American professor of dentistry
was conducting a project related to oral health. This intro-
duction implicitly suggested an "expert consultation", and
may have induced some patients to participate. At the
same time, patients satisfied with their current level of
oral care may have declined this invitation. The sample
was taken only from those patients under care of the
Shaare Zedek Medical Center Gaucher Disease clinic.
This is a "pathfinder investigation" and the authors are
aware of the limitations. An initial study will have many
imperfections and represents a compromise with optimal
design. Such a study need not be perfect. [23]. Consider-
ing the rarity of Gaucher disease and the unique opportu-
nity to study this population in this specialized clinic,
never the less these results are of interest and we believe of
significant value.
These data represent the first survey of the oral health of a
large cohort of patients with Gaucher disease. Although
the literature cites case reports of oral signs and symp-
toms, this population was devoid of significant abnormal-
ities, suggesting that patients previously reported in the
literature represent those who sought consultation for
oral symptoms and were not typical of this special need
population.
These results are preliminary, but valuable, indications of
the oral health status of Gaucher disease patients. Future
studies should include an evaluation of the oral hygiene
status (plaque level and calculus scores), oral health edu-
cation, and a disciplined review of the patients' profes-
sional dental care. A comparison of oral health findings in
a cohort of healthy Israeli Ashkenazi Jews is also
indicated.
Conclusions
Based on these findings, we recommend regular and thor-
ough oral examination, with appropriate dental treat-
ment, for patients with Gaucher disease as for other
individuals. Enzyme replacement therapy, either with the
placental-derivative Ceredase®  (Genzyme Therapeutics
Inc, Cambridge MA) or the recombinant product
Cerezyme®, reduces the complications of hypersplenism,
improving hemoglobin and increasing platelet counts
[24,25], as well as decreasing the tendency to infections
[26].
Because many of the Gaucher disease patients (42%) had
thrombocytopenia, the dentist should consult with the
patient's primary care physician when the treatment plan
includes procedures likely to cause bleeding. This would
include scaling, root planing and curettage, extractions,
periodontal surgery, and other oral surgical procedures. It
would be preferable for this consultation to include a phy-
sician experienced in managing Gaucher disease or a
hematologist. In addition, partial factor deficiencies, such
as of factors IX and XI, are not uncommon in Ashkenazi
Jews [27]. This deficiency should also be considered in
patients with Gaucher disease. Antibiotic prophylaxis
before and after deep scaling and similar procedures has
been suggested for splenectomized patients as well as in
patients with a history of systemic infections [28].
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